Deferred Income Tax Expense (Benefit) in USD of Lineage Cell Therapeutics, Inc. from 2011 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Lineage Cell Therapeutics, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2011 to Q1 2025.
  • Lineage Cell Therapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2025 was $0.000.
  • Lineage Cell Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2024 was $0.000.
  • Lineage Cell Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$1.8M.
  • Lineage Cell Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was $0.000.
Deferred Income Tax Expense (Benefit), Trailing 12 Months (USD)
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)

Lineage Cell Therapeutics, Inc. Quarterly Deferred Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $0 $0 Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-13
Q3 2024 $0 $0 Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q1 2024 $0 +$1.8M Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-13
Q3 2023 $0 Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q1 2023 -$1.8M Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-14
Q3 2021 -$1.01M -$834K -469% Jul 1, 2021 Sep 30, 2021 10-Q 2021-11-10
Q2 2021 -$169K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q3 2020 -$178K +$813K +82% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q3 2019 -$991K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 -$1.25M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$4.38M Jan 1, 2019 Mar 31, 2019 10-Q 2019-05-09
Q3 2017 $4.8M $4.77M +$4.77M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $23K -$3.88M -$3.88M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $3.9M $3.9M +$3.9M Jan 1, 2017 Mar 31, 2017 10-Q 2018-08-02
Q4 2016 $0 $0 +$1.12M Oct 1, 2016 Dec 31, 2016 10-K 2017-03-16
Q3 2016 -$1.12M $0 +$948K Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 -$2.07M $0 +$1.27M Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 -$3.34M $0 +$1.18M Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q4 2015 -$4.52M -$1.12M +$1.08M +49.1% Oct 1, 2015 Dec 31, 2015 10-K 2018-03-15
Q3 2015 -$5.6M -$948K +$1.37M +59% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-04
Q2 2015 -$6.96M -$1.27M +$242K +16% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 -$7.2M -$1.18M +$172K +12.8% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q4 2014 -$7.38M -$2.2M Oct 1, 2014 Dec 31, 2014 10-K 2017-03-16
Q3 2014 -$2.31M Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-09
Q2 2014 -$1.51M Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-10
Q1 2014 -$1.35M -$1.35M Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-08
Q1 2013 $0 Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-12

Lineage Cell Therapeutics, Inc. Annual Deferred Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $0 +$1.8M Jan 1, 2024 Dec 31, 2024 10-K 2025-03-10
2023 -$1.8M -$1.8M Jan 1, 2023 Dec 31, 2023 10-K 2025-03-10
2022 $0 Jan 1, 2022 Dec 31, 2022 10-K 2024-03-07
2020 -$1.24M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-10
2016 $0 +$4.52M Jan 1, 2016 Dec 31, 2016 10-K 2017-03-16
2015 -$4.52M +$2.86M +38.8% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-15
2014 -$7.38M -$4.1M -125% Jan 1, 2014 Dec 31, 2014 10-K 2017-03-16
2013 -$3.28M -$3.28M Jan 1, 2013 Dec 31, 2013 10-K 2016-03-15
2012 $0 $0 Jan 1, 2012 Dec 31, 2012 10-K 2015-03-11
2011 $0 Jan 1, 2011 Dec 31, 2011 10-K 2014-03-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.